Jack Bendheim, President and CEO of Phibro Animal Health Corporation, sold 72,198 shares indirectly for approximately $3.74 million between February 10-11, 2026, under a pre-existing Rule 10b5-1 trading plan. The sale occurred following strong Q2 2026 earnings with year-over-year growth in revenue, net income, and EPS. The company's medicated feed additive portfolio has grown faster than expected, particularly following its late 2024 acquisition of over 37 product lines.

The global glycolic acid market is projected to grow at a CAGR of 5.73% from 2026 to 2032, reaching USD 461.74 Million by 2032, up from USD 295.68 Million in 2024. Growth is driven by increasing demand in personal care, pharmaceuticals, and industrial cleaning applications, though regulatory challenges and raw material price volatility pose restraints.

Phibro Animal Health reported strong Q4 FY2025 earnings, with 39% revenue growth driven by the Zoetis medicated feed additive acquisition. Despite robust sales and adjusted EBITDA, gross margins declined due to higher distribution costs and product mix challenges.

The article recommends two value stocks to buy for February 14th: Adtalem Global Education (ATGE) and Phibro Animal Health (PAHC). Both companies have a Zacks Rank #1 and have seen their earnings estimates increase in the last 60 days, indicating positive sentiment.

The poultry pharmaceuticals market is dominated by vaccines due to rising concerns over infectious diseases and regulatory restrictions on antibiotics. The market is projected to reach $6.68 billion by 2029, driven by increasing poultry consumption and the need for effective disease management.

The porcine vaccine market is forecasted to grow by USD 709.6 million during 2023-2028, driven by increasing prevalence of porcine diseases, research and development, and growing animal healthcare expenditure.

The UAE Veterinary Medicine Market is experiencing a healthy trajectory, driven by technological innovations, escalating demand for animal healthcare, and concerns over zoonotic diseases. The market is expected to grow at a CAGR of 4.35% from 2023 to 2029, reaching a value of USD 69.32 million by 2029.

The global animal feed minerals market is projected to grow at a CAGR of 3.9% from 2024 to 2034, driven by the rising demand for nutrient-dense feed supplements to enhance animal health and productivity. Asia-Pacific is expected to dominate the market, attributed to the expanding livestock industry in countries like China and India.

The poultry vaccines market is projected to grow from $2.1 billion in 2023 to $4.1 billion by 2031, driven by the rising prevalence of poultry diseases. Advancements in vectored and combination vaccines are expected to be key market trends.

Phibro Animal Health Corporation's robust sales of vaccines and medicated feed additives (MFAs) are driving growth in its Animal Health business. The company's focus on advancing nutritional specialties and vaccine technologies, along with a new vaccine production unit, instills optimism. However, adverse macroeconomic impacts and growing competition from generic alternatives are concerns.

The global swine healthcare market is expected to grow from USD 2.72 billion in 2023 to USD 5.96 billion by 2033, driven by increasing demand for pork products, especially in emerging markets. The market is segmented by product (diagnostics and therapeutics) and disease (respiratory, swine dysentery, etc.), with the therapeutics segment and respiratory diseases segment expected to hold the largest shares.

The article highlights five small-cap value stocks with strong growth potential, including Great Lakes Dredge & Dock, HanesBrands, Lands' End, Phibro Animal Health, and Wolverine World Wide.